Regorafenib
- Generic Name
- Regorafenib
- Brand Names
- Stivarga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H15ClF4N4O3
- CAS Number
- 755037-03-7
- Unique Ingredient Identifier
- 24T2A1DOYB
- Background
Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in April 2017.
- Indication
Regorafenib is indicated for the treatment of patients with metastatic colorectal cancer (CRC) who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and, if KRAS wild type, an anti-EGFR therapy. Regorafenib is also indicated for the treatment of patients with locally advanced, unresecta...
- Associated Conditions
- Hepatocellular Carcinoma, Metastatic Colorectal Cancer (CRC), Metastatic Gastrointestinal Stromal Tumor (GIST), Locally advanced Gastrointestinal stromal tumor, Unresectable Gastrointestinal stromal tumor
- Associated Therapies
- -
A Phase 2 Randomized, Open-Label Study of RRx-001 vs Regorafenib in Subjects With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- EpicentRx, Inc.
- Target Recruit Count
- 62
- Registration Number
- NCT02096354
- Locations
- ๐บ๐ธ
UCSD Moores Cancer Center, La Jolla, California, United States
๐บ๐ธKaiser Permanete, Honolulu, Hawaii, United States
๐บ๐ธStanford University, Stanford, California, United States
Regorafenib and Cetuximab in Patients With Advanced Malignancy
- Conditions
- Interventions
- First Posted Date
- 2014-03-24
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 39
- Registration Number
- NCT02095054
- Locations
- ๐บ๐ธ
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
A Study of Regorafenib in Advanced Pancreatic Cancer Patients
- First Posted Date
- 2014-03-06
- Last Posted Date
- 2022-04-21
- Lead Sponsor
- Wake Forest University Health Sciences
- Target Recruit Count
- 20
- Registration Number
- NCT02080260
- Locations
- ๐บ๐ธ
Low Country Hematology Oncology, Charleston, South Carolina, United States
๐บ๐ธLevine Cancer Institute-Albemarle, Albemarle, North Carolina, United States
๐บ๐ธLevine Cancer Institute-South Tryon, Charlotte, North Carolina, United States
A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy
- First Posted Date
- 2014-02-03
- Last Posted Date
- 2019-01-30
- Lead Sponsor
- Nathan Bahary, MD
- Target Recruit Count
- 43
- Registration Number
- NCT02053376
- Locations
- ๐บ๐ธ
UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2023-11-07
- Target Recruit Count
- 131
- Registration Number
- NCT02048371
- Locations
- ๐บ๐ธ
Children's Hospital Los Angeles, Los Angeles, California, United States
๐บ๐ธSarcoma Oncology Research Center, Santa Monica, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
Daily Oral Regorafenib for Chemotherapy-Refractory, Metastatic and Locally Advanced Angiosarcoma
- Conditions
- Interventions
- First Posted Date
- 2014-01-29
- Last Posted Date
- 2022-04-25
- Lead Sponsor
- Northwestern University
- Target Recruit Count
- 31
- Registration Number
- NCT02048722
- Locations
- ๐บ๐ธ
Sarcoma Oncology Center, Santa Monica, California, United States
๐บ๐ธNorthwestern University, Chicago, Illinois, United States
๐บ๐ธWashington University-St. Louis, Saint Louis, Missouri, United States
A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2023-11-15
- Lead Sponsor
- Sumitomo Pharma America, Inc.
- Target Recruit Count
- 495
- Registration Number
- NCT02024607
- Locations
- ๐บ๐ธ
Parkview Research Center, Fort Wayne, Indiana, United States
๐บ๐ธEmory University Winship Cancer Institute, Atlanta, Georgia, United States
๐บ๐ธIndiana University Health Goshen Center for Cancer Care, Goshen, Indiana, United States
Regorafenib in Good Performance Status Patients With Newly Diagnosed Metastatic Colorectal Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2013-12-30
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 11
- Registration Number
- NCT02023333
- Locations
- ๐บ๐ธ
Memorial Sloan Kettering Cancer Center at Basking Ridge, Basking Ridge, New Jersey, United States
๐บ๐ธMemorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States
๐บ๐ธQueens Cancer Center of Queens Hospital, Jamaica, New York, United States
Identification of Predictive Biomarker of Regorafenib in Refractory Colorectal Cancer
- First Posted Date
- 2013-11-27
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Seoul National University Hospital
- Target Recruit Count
- 117
- Registration Number
- NCT01996969
- Locations
- ๐ฐ๐ท
Seoul National University Hospital, Seoul, Korea, Republic of
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
- First Posted Date
- 2013-09-24
- Last Posted Date
- 2018-08-10
- Lead Sponsor
- Gerald Batist
- Target Recruit Count
- 48
- Registration Number
- NCT01949194
- Locations
- ๐จ๐ฆ
McGill University Health Centre, Montrรฉal, Quebec, Canada
๐จ๐ฆHopital Maisonneuve-Rosemont, Montreal, Canada
๐จ๐ฆSt-Mary's Hospital Centre, Montreal, Quebec, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.